No products in the cart.
Retatrutide | 30mg Peptide Pen
€340.00
If you’re looking to buy Retatrutide, DN Research offers the highest-quality peptides with over 99% purity. Produced in European, GMP state-of-the-art laboratories, our peptides are trusted for scientific research and development.
✓ Fast Delivery
✓ Premium Quality
✓ 3rd Party Tested
In Stock
CompareDescription
Retatrutide | 30mg Pen Calculation:
One pen contains 300 units of 100 micrograms.
(1 unit equals 1 division on the doser)
Examples of calculated units per pen of Retatrutide (30mg) corresponding to micrograms:
1 unit = 100 mcg
4 units = 400 mcg
6 units = 600 mcg
8 units = 800 mcg
10 units = 1 mg
Storage and Shipping Guidelines
- Refrigeration: Store at 2–8°C to maintain quality and effectiveness.
- 1-Year Plus Shelf Life: Retains full efficacy for up to one year when properly refrigerated.
- Shipping: Pens are shipped with ice packs to ensure proper temperature control.
- Temperature Tolerance: Remains stable below 25°C but should not be exposed to higher temperatures.
- Avoid Freezing: Do not freeze, as this may compromise stability and effectiveness.
MADE IN EUROPE. Products from this Web Site are NOT intended to be used to diagnose or treat any medical condition or disease. Products on this website are sold for laboratory research purposes only and are for in-vitro lab research use only.
The products are not medicines or drugs and they have not been approved by the fda to prevent, treat, diagnose, mitigate, or cure any disease, ailment or medical condition.
Frequently Bought Together
Related products
FAQs
No, Retatrutide is not the same as Ozempic (Semaglutide). While both are used to support weight loss and metabolic health, they work through different biological pathways. Retatrutide activates three hormone receptors simultaneously, offering a broader mechanism of action. In contrast, Ozempic targets just one. This difference in receptor activity leads to distinct therapeutic profiles.
- Retatrutide and tirzepatide differ in hormone targeting but show comparable results. Retatrutide mimics three metabolic hormones, while tirzepatide targets two. Despite this difference, clinical data to date suggests similar efficacy: tirzepatide has shown average weight loss of ~25% after 52 weeks, while retatrutide reports ~24% after 48 weeks.
- Early clinical data on retatrutide is striking. Participants lost up to 25% of their body weight in less than a year—nearly double the average outcomes seen with Ozempic. Unlike many other weight loss therapies that primarily curb appetite, retatrutide also appears to enhance metabolic rate, amplifying fat loss through multiple mechanisms.
Retatrutide has shown promising effects on both weight reduction and metabolic health in adults with obesity, with a safety profile consistent with early expectations. Still, larger and longer-term studies are needed to confirm these findings and fully understand its therapeutic potential.
Retatrutide marks a promising advance in obesity therapeutics, delivering a multi-targeted approach that supports fat loss while helping preserve lean muscle mass. This dual action distinguishes it from many existing treatments and underscores its potential as a next-generation metabolic intervention.